Tweets
Predictors of serious infection (SIE) in SLE? A prior SIE conferred the highest risk of subsequent SIE. Study of 346 SLE pts shows SIE rate of 3.8/100 Pt-Yrs. Other risk factors:
Damage accrual, comorbidity, Dz activity, CTX use https://t.co/hvAtpTUPml https://t.co/QkJp7ssOUU
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Hematoinflammatory diseases https://t.co/3Xd76ab7yP
Luis Caminal @caminalm ( View Tweet )
3 years 8 months ago
⏫IgG4 🚫 IgG4 RD
Elevated IgG4 levels can be seen:
👉 Chronic infections like #tuberculosis
👉Lymphoproliferative malignancies
👉 Bronchiectasis, #asthma
👉 Primary sclerosing cholangitis
#RheumTwitter #MedTwitter #Rheumatology https://t.co/N3EDYjyFLf
Pankti Mehta @PanktiMehta24 ( View Tweet )
3 years 8 months ago
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
https://t.co/cpOTUsok7e https://t.co/5Ew7Hr9Mcd
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia.
https://t.co/0DOBvpsV6r https://t.co/T8VrFlu6xq
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
CONGRATS to Dr Jean Liew: from Bronte scholar to social media influencer https://t.co/f9ZrvxaPgB
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
https://t.co/ieaYyznlec https://t.co/YafTOxh8Cr
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
Update to Axial Spondyloarthritis Guidance
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
https://t.co/XQId2RIaVz https://t.co/vNRYSV2jRh
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
https://t.co/frGedFHVuU https://t.co/I9B4YjcqLa
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago


